PATENT CLAIM ANALYSIS

Application Number: 15884699
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["514", "217000"]

Abstract:
Methods of treating developmental disorders by administering a pharmaceutical composition of pipradrol or a pharmaceutically acceptable salt thereof are provided. The methods may be used to treat conditions such as epilepsy, Landau-Kleffner Syndrome, Lennox-Gastaut syndrome (LGS) and Dravet syndrome.

Claim (Index 6):
The method of  claim 1  wherein the developmental disorder is a sodium channel protein type 1 subunit alpha (Scn1A)-related seizures disorder selected from the group consisting of generalized epilepsy with fibrile seizures plus, intractable childhood epilepsy with generalized tonic-clonic seizures, intractable infantile partial seizures, myoclonic-astatic epilepsy, severe myoclonic epilepsy in infancy, simple febrile seizures, Lennox-Gastaut syndrome (LGS), infantile spasms, and vaccine-related encephalopathy and seizures.

Metadata:
- Claim Count in Document: 13.0
- Percentile: 86.0
- Lexical Diversity: 1.125
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15493374', '14876110', '15191068', '15680417', '14240847']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7809641059893536
- 35 USC 102 Novelty (BERT): 0.536068379578368
- Combined Prediction Score: 0.7564745333482551
- Mean Citation Score: 331.83315
- Max Citation Score: 371.2598
- Similarity Product: 282.0864109841108

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test